We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

FTC/RPV/TDF on T-Cell Activation, CD4+ T-Cell Count, Inflammatory Biomarkers and Viral Reservoir

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01777997
Recruitment Status : Completed
First Posted : January 29, 2013
Results First Posted : January 12, 2018
Last Update Posted : January 12, 2018
Sponsor:
Collaborator:
National Institute of Allergy and Infectious Diseases (NIAID)
Information provided by (Responsible Party):
AIDS Clinical Trials Group

Brief Summary:

This study was done with people who were infected with HIV, but did not show any signs of having HIV. They were also feeling well without taking HIV medication and had low or undetectable levels of the virus in the blood. The purpose of this study was to see if taking HIV medication (antiretroviral therapy [ART]) would reduce immune activation (a signal that the body is fighting an infection) in people who have HIV, but did not show symptoms. Also this study helped determine how safe the drug was and how well people reacted to the drug.

For this study, the following antiretroviral therapy (ART) was be provided in the form of a single tablet that contains three different drugs: emtricitabine/rilpivirine/tenofovir disoproxil fumarate (FTC/RPV/TDF). These drugs were combined as one tablet which was approved by the Food and Drug Administration (FDA) as a single pill to treat HIV infection. The HIV medication provided was one of the recommended treatments for HIV, including people with low viral loads (how much HIV you have in your body) who were taking HIV drugs for the first time. The risks seen with this HIV medication were the same that one would encounter when taking these drugs outside of the study.


Condition or disease Intervention/treatment Phase
HIV-1 Infection Drug: Emtricitabine/rilpivirine/tenofovir disoproxil fumarate Phase 4

Detailed Description:

AIDS Clinical Trials Group (ACTG) A5308 was a single-arm clinical trial to evaluate the effect of initiating fixed-dose combination (FDC) FTC/RPV/TDF on CD8+ T-cell activation and other immunologic and virologic biomarkers among treatment-naïve HIV-1 controllers with any absolute CD4+ T-cell count. At study entry, these participants were followed off ART for a 12-week lead-in period, and then at week 12, participants initiated FDC FTC/RPV/TDF and had 48 weeks of follow-up to evaluate the primary endpoint.

All participants who completed Step 1 (48 weeks of ART) had the option to register to Step 2, for an additional 48 weeks of follow-up, and had the choice of either continuing FDC FTC/RPV/TDF or follow-up with no study treatment.

Participants underwent safety and tolerability evaluations throughout the study, including physical examinations and clinical assessments. Pregnancy tests were performed on women of childbearing potential. Collection of stored blood plasma/peripheral blood mononuclear cell (PBMC) samples occurred at entry and weeks 0, 4, 12, 24, 36, 48, 60, 72 and 96 on ART.

Only participants who were on intervention (ART) for at least 24 weeks had samples sent for testing of immunologic and virologic biomarkers.


Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 38 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Prospective, Single-Arm, Open-Label Study to Evaluate the Effect of Fixed-Dose Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate on T-Cell Activation, Absolute CD4+ T-Cell Count, Inflammatory Biomarkers and Viral Reservoir in Treatment-Naïve HIV-1 Controllers
Actual Study Start Date : April 25, 2013
Primary Completion Date : February 19, 2016
Study Completion Date : February 7, 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: HIV/AIDS
U.S. FDA Resources

Arm Intervention/treatment
Experimental: FTC/RPV/TDF

Step 1: From entry through week 12, the participants received no study treatment. From week 12 through week 60, the participants received one fixed dose combination emtricitabine/rilpivirine/tenofovir disoproxil fumarate (FTC/RPV/TDF) tablet daily.

Step 2 (Optional): From week 60 through week 108, the participants either received one FTC/RPV/TDF tablet daily or no study treatment.

Drug: Emtricitabine/rilpivirine/tenofovir disoproxil fumarate
Other Names:
  • FTC/RPV/TDF
  • Complera



Primary Outcome Measures :
  1. Change in Levels of CD8+ T-cell Activation (Defined as the Percentage HLA-DR+/CD38+) From Baseline to Weeks 24 and 48 on ART [ Time Frame: From baseline (pre-ART and week 0 on ART) to weeks 24 and 48 on ART ]
    Mean change from baseline (pre-ART [study entry] and week 0 on ART [study week 12]), estimated with a repeated measures analysis (jointly to weeks 24 and 48 on ART) using generalized estimating equations (GEE)


Secondary Outcome Measures :
  1. Plasma HIV-1 RNA Level Measured by Single Copy Assay Using Primer in Integrase (iSCA) as the Proportion of Participants Below the Limit of the Assay [ Time Frame: At pre-ART and weeks 0, 4, 12, 24, 36 and 48 on ART ]
    At a specific week, the proportion of participants with HIV-1 RNA by iSCA less than assay limit of detection (0.6 copies/mL)

  2. Change in CD4+ T-cell Count [ Time Frame: From baseline (pre-ART and week 0 on ART) to weeks 12, 24, 36 and 48 on ART ]
    Change equals each specific week CD4+ T-cell count, respectively, minus the baseline CD4+ T-cell count (mean of the two measurements obtained prior to the start of ART)

  3. Change in Levels of CD8+ T-cell Activation [ Time Frame: From baseline (pre-ART and week 0 on ART) to weeks 4, 12, 24 and 48 on ART ]
    Change equals each specific week percentage, respectively, minus the baseline percentage (mean of the two measurements obtained prior to the start of ART)

  4. Change in Levels of CD4+ T-cell Activation (Defined as the Percentage HLA-DR+/CD38+) [ Time Frame: From baseline (pre-ART and week 0 on ART) to weeks 4, 12, 24 and 48 on ART ]
    Change equals each specific week percentage, respectively, minus the baseline percentage (mean of the two measurements obtained prior to the start of ART)

  5. Change in Levels of Interleukin (IL)-6 [ Time Frame: From baseline (pre-ART and week 0 on ART) to weeks 4, 12, 24 and 48 on ART ]
    Change equals each specific week result, respectively, minus the baseline result (mean of the two log10-transformed measurements obtained prior to the start of ART)

  6. Change in Levels of D-dimer [ Time Frame: From baseline (pre-ART and week 0 on ART) to weeks 4, 24 and 48 on ART ]
    Change equals each specific week result, respectively, minus the baseline result (mean of the two log10-transformed measurements obtained prior to the start of ART)

  7. Change in Quality of Life (QoL) Index [ Time Frame: From baseline (pre-ART and week 0 on ART) to weeks 4, 24 and 48 on ART ]
    QoL index was obtained by averaging the five responses on the Euro-Quality of Life questionnaire (EQ-5D), where a response of 0 indicates "no problems/no discomfort", 1 indicates "some problems/moderate discomfort" and 2 indicates "unable to perform activities/extreme discomfort". Change equals each specific week index, respectively, minus the baseline index (mean of the two averages obtained prior to the start of ART)

  8. Number of Subjects Who Experience Grade 3 or 4 Signs and Symptoms or Laboratory Abnormalities, Diagnoses (Any Grade), or Other Serious Adverse Events (SAEs) [ Time Frame: From initiation of treatment to study completion at week 60 or 108 or premature study discontinuation ]
    Grading uses the Division of AIDS (DAIDS) 2004 (clarification 2009) Severity of Adverse Events Table, where Grade 1=Mild, 2=Moderate, 3=Severe, 4=Potentially life-threatening.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Step 1

  • HIV-1 infection
  • ART-naïve defined as ≤7 days of antiretroviral (ARV) treatment at any time prior to entry
  • Documentation of HIV-1 RNA <500 copies/mL verified by at least two measurements prior to the screening RNA specimen
  • Screening HIV-1 RNA <500 copies/mL using an US FDA-approved assay obtained within 60 days prior to study entry by any laboratory that has a CLIA certification or its equivalent
  • Laboratory values obtained within 60 days prior to entry by any laboratory that has a CLIA certification or its equivalent:

    • Absolute neutrophil count (ANC) >=500/mm^3
    • Hemoglobin >=8.0 g/dL
    • Platelet count >=40,000/mm^3
    • Aspartate aminotransferase (AST) (SGOT), alanine aminotransferase (ALT) (SGPT), and alkaline phosphatase <=5 X Upper Limit of Normal (ULN)
    • Total bilirubin <=2.5 X ULN
    • Calculated creatinine clearance (CrCl) >=60 mL/min
  • For females of reproductive potential, negative serum or urine pregnancy test within 48 hours prior to study entry by any clinic or laboratory that has a CLIA certification or its equivalent
  • Female subjects of reproductive potential, who are participating in sexual activity that could lead to pregnancy, must agree to use at least one reliable form of contraceptive (ie, condoms (male or female) with or without a spermicidal agent; a diaphragm or cervical cap with spermicide; an intrauterine device (IUD); or hormone-based contraceptive) while receiving the protocol-specified treatment and for 6 weeks after stopping the medications
  • No evidence of any exclusionary resistance mutations based on results from any genotype assay from any laboratory that has a Clinical Laboratory Improvement Amendments (CLIA) certification or its equivalent

Step 2

  • Completion of Step 1
  • Ability and willingness of subject to choose to receive either open-label ART FDC (FTC/RPV/TDF) or no study treatment for an additional 48 weeks
  • For females of reproductive potential, negative serum or urine pregnancy test within 48 hours prior to the week 60 visit by any clinic or laboratory that has a CLIA certification or its equivalent

Exclusion Criteria:

Step 1

  • Chronic hepatitis B virus (HBV) infection (documented by hepatitis B surface antigen (HBsAg) seropositivity)
  • Breastfeeding
  • Use of immunomodulators (eg, interleukins, interferons, cyclosporine), topical imiquimod, HIV vaccine, systemic cytotoxic chemotherapy, or investigational therapy within 30 days prior to study entry or plans to start immunomodulators, topical imiquimod, HIV vaccine, systemic cytotoxic chemotherapy, or investigational therapy during the study
  • Known allergy/sensitivity or any hypersensitivity to components of study drug(s) or their formulation
  • Active drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements
  • Acute or serious illness requiring systemic treatment and/or hospitalization within 30 days prior to entry
  • Symptomatic HIV disease and/or AIDS-defining illness.
  • Vaccinations within 7 days prior to study entry
  • Plans to initiate hepatitis C treatment during the study
  • Perinatally-acquired HIV
  • Use of any of the following medications within 7 days prior to study entry:

    • St. John's wort (Hypercium perforatum)
    • Anticonvulsants (eg, oxacarbazepine, phenobarbital, phenytoin)
    • Anti-infectives (eg, rifabutin, rifampin, rifapentine)
    • Corticosteroids (eg, dexamethasone (more than 1 dose))
    • Proton pump inhibitors (eg, esomeprazole, lansoprazole, omeprazole, pantoprazole, rabeprazole)

Step 2

  • Plans to start immunomodulators, topical imiquimod, HIV vaccine, systemic cytotoxic chemotherapy, or investigational therapy during Step 2 of the study
  • Plans to initiate hepatitis C treatment during Step 2 of the study

NOTE: Please refer to the protocol for detailed eligibility criteria.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01777997


Locations
United States, Alabama
31788 Alabama CRS
Birmingham, Alabama, United States, 35294
United States, California
801 University of California, San Francisco HIV/AIDS CRS
San Francisco, California, United States, 94110
United States, District of Columbia
Whitman Walker Health CRS (31791)
Washington, District of Columbia, United States, 20009
United States, Georgia
The Ponce de Leon Ctr. CRS (5802)
Atlanta, Georgia, United States, 30308
United States, Illinois
Northwestern University CRS (2701)
Chicago, Illinois, United States, 60611
Rush Univ. Med. Ctr. ACTG CRS (2702)
Chicago, Illinois, United States, 60612
United States, Maryland
IHV Baltimore Treatment CRS (4651)
Baltimore, Maryland, United States, 21201
United States, Massachusetts
Massachusetts General Hospital ACTG CRS (101)
Boston, Massachusetts, United States, 02114
Brigham and Women's Hosp. ACTG CRS (107)
Boston, Massachusetts, United States, 02115
United States, New York
Bronx-Lebanon Hosp. Ctr. CRS (31469)
Bronx, New York, United States, 10457
University of Rochester Adult HIV Therapeutic Strategies Network CRS (31787)
Rochester, New York, United States, 14642
United States, North Carolina
Unc Aids Crs (3201)
Chapel Hill, North Carolina, United States, 27516
Moses H. Cone Memorial Hospital CRS (3203)
Greensboro, North Carolina, United States, 27401
United States, Ohio
University of Cincinnati CRS (2401)
Cincinnati, Ohio, United States, 45267
Metro Health CRS (2503)
Cleveland, Ohio, United States, 44109
United States, Pennsylvania
Hosp. of the Univ. of Pennsylvania CRS (6201)
Philadelphia, Pennsylvania, United States, 19104
Pitt CRS (1001)
Pittsburgh, Pennsylvania, United States, 15213
United States, Rhode Island
The Miriam Hosp. ACTG CRS (2951)
Providence, Rhode Island, United States, 02906
United States, Texas
Houston AIDS Research Team CRS (31473)
Houston, Texas, United States, 77030
Sponsors and Collaborators
AIDS Clinical Trials Group
National Institute of Allergy and Infectious Diseases (NIAID)
Investigators
Study Chair: Jonathan Li, M.D., M.M.S. Brigham and Women's Hospital Therapeutics (BWHT) CRS

Additional Information:
Responsible Party: AIDS Clinical Trials Group
ClinicalTrials.gov Identifier: NCT01777997     History of Changes
Other Study ID Numbers: ACTG A5308
1U01AI068636 ( U.S. NIH Grant/Contract )
First Posted: January 29, 2013    Key Record Dates
Results First Posted: January 12, 2018
Last Update Posted: January 12, 2018
Last Verified: December 2017

Additional relevant MeSH terms:
Tenofovir
Emtricitabine
Rilpivirine
Antiviral Agents
Anti-Infective Agents
Reverse Transcriptase Inhibitors
Nucleic Acid Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-Retroviral Agents
Anti-HIV Agents